Tenax Therapeutics, Inc. — Form 8-K Summary
Reporting date: October 8, 2026. This is a current report of a clinical-development update, not a periodic financial report.
Business context and material update
Tenax is modifying its LEVEL-2 clinical trial of TNX-103 in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), based on learnings from its recently completed Phase 3 LEVEL trial. The company intends to amend LEVEL-2 enrollment criteria to focus on patients its interpretation of LEVEL results suggests are most likely to show improved exercise tolerance on the trial’s primary endpoint.
LEVEL-2 enrollment has been temporarily paused while the protocol is amended. Enrollment may resume at individual sites as the amended protocol takes effect at each site.
Financial information
The 8-K provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics, and does not present a comparable-period financial analysis.
Outlook, risks, and contingencies
Tenax has requested a Type C meeting with the FDA to discuss the overall development of levosimendan. The filing does not provide a meeting date, FDA response, or outcome. Trial timing and enrollment could be affected by implementation of the amended protocol across sites. The company’s updated investor presentation is identified as Exhibit 99.1, but its substantive contents are not included in the supplied filing text.
Important facts for investors to verify
- The final amended LEVEL-2 eligibility criteria and which patient groups will qualify.
- When enrollment resumes at each site and any resulting impact on trial timing.
- The FDA’s response to the Type C meeting request and any subsequent development-plan changes.
- The detailed LEVEL-2 and LEVEL results and rationale in the full Exhibit 99.1 presentation.